Researchers are testing gene therapies that aim to protect, and possibly restore, the optic nerve cells that glaucoma damages. Early results are promising, and the first human trial is under way, but no gene therapy is approved for glaucoma yet.
Clinical trials only. Not offered at VitalX.
See the research (4)
- Evaluating ER-100 for safety in people with glaucoma or NAION (Phase 1, recruiting)ClinicalTrials.gov, NCT07290244
- Reprogramming to recover youthful epigenetic information and restore visionLu et al., Nature, 2020
- First patient dosed in the Phase 1 trial of ER-100 for optic neuropathiesLife Biosciences, trial sponsor
- A revolutionary approach to restoring vision loss from glaucomaBrightFocus Foundation


